A New Hypoxia-Related Prognostic Risk Score (HPRS) Model Was Developed to Indicate Prognosis and Response to Immunotherapy for Lung Adenocarcinoma

Figure 7

Comparison of prognostic ability between HPRS and traditional clinical indexes. (a): Meta-analysis was performed to calculate the pooled HR of TNM staging classification. (b-d): OS of patients undergoing HPRS grouping in stage I, stage II, and stage IV patients, respectively. (e): OS analysis of stage II-IV patients compared with stage. (f): Meta-analysis of the correlation between HPRS and LUAD prognoses in 853 LUAD samples. (g): The survival curves of high HPRS group and low HPRS group were measured in 853 LUAD samples.

(a)

(b)

(c)

(d)

(e)

(f)

(g)